EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand

Ajala Prommi, Kanphai Wongjarit iD, Suthidee Petsong, Ubonwan Somsukpiroh, Kiatichai Faksri iD, Kamon Kawkitinarong, Sunchai Payungporn iD, Suwatchareeporn Rotcheewaphan iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.03462-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Ajala Prommi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CU | Faculty of Medicine, Chulalongkorn University (MDCU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isoniazid-resistant tuberculosis (Hr-TB) is an important drug-resistant tuberculosis (TB). In addition to rifampicin, resistance to other medications for Hr-TB can impact the course of treatment; however, there are currently limited data in the literature. In this study, the drug susceptibility profiles of Hr-TB treatment and resistance-conferring mutations were investigated for Hr-TB clinical isolates from Thailand. Phenotypic drug susceptibility testing (pDST) and genotypic drug susceptibility testing (gDST) were retrospectively and prospectively investigated using the Mycobacterium Growth Indicator Tube (MGIT), the broth microdilution (BMD) method, and whole-genome sequencing (WGS)-based gDST. The prevalence of Hr-TB cases was 11.2% among patients with TB. Most Hr-TB cases (89.5%) were newly diagnosed patients with TB. In the pDST analysis, approximately 55.6% (60/108) of the tested Hr-TB clinical isolates exhibited high-level isoniazid resistance. In addition, the Hr-TB clinical isolates presented co-resistance to ethambutol (3/161, 1.9%), levofloxacin (2/96, 2.1%), and pyrazinamide (24/118, 20.3%). In 56 Hr-TB clinical isolates, WGS-based gDST predicted resistance to isoniazid [ katG S315T (48.2%) and fabG1 c-15t (26.8%)], rifampicin [ rpoB L430P and rpoB L452P (5.4%)], and fluoroquinolones [ gyrA D94G (1.8%)], but no mutation for ethambutol was detected. The categorical agreement for the detection of resistance to isoniazid, rifampicin, ethambutol, and levofloxacin between WGS-based gDST and the MGIT or the BMD method ranged from 80.4% to 98.2% or 82.1% to 100%, respectively. pDST and gDST demonstrated a low co-resistance rate between isoniazid and second-line TB drugs in Hr-TB clinical isolates. IMPORTANCE The prevalence of isoniazid-resistant tuberculosis (Hr-TB) is the highest among other types of drug-resistant tuberculosis. Currently, the World Health Organization (WHO) guidelines recommend the treatment of Hr-TB with rifampicin, ethambutol, pyrazinamide, and levofloxacin for 6 months. The susceptibility profiles of Hr-TB clinical isolates, especially when they are co-resistant to second-line drugs, are critical in the selection of the appropriate treatment regimen to prevent treatment failure. This study highlights the susceptibility profiles of the WHO-recommended treatment regimen in Hr-TB clinical isolates from a tertiary care hospital in Thailand and the concordance and importance of using the phenotypic drug susceptibility testing or genotypic drug susceptibility testing for accurate and comprehensive interpretation of results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansAntitubercular AgentsIsoniazidPyrazinamideEthambutolRifampinLevofloxacinThailandMicrobial Sensitivity TestsRetrospective StudiesTertiary Care CentersMutation

Stichwörter der Autor:innen

Mycobacterium tuberculosisdrug susceptibility profileisoniazid-resistant tuberculosiswhole-genome sequencing

Substanzen

Antitubercular AgentsIsoniazidPyrazinamideEthambutolRifampinLevofloxacin

Autor:innen und Institutionen

  • Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Systems Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Microbiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

ORCID-Profile: Kanphai Wongjarit, Kiatichai Faksri, Sunchai Payungporn, Suwatchareeporn Rotcheewaphan

Förderung

  • CU | Faculty of Medicine, Chulalongkorn University (MDCU)

Zitieren

APA

Prommi, A., Wongjarit, K., Petsong, S., Somsukpiroh, U., Faksri, K., Kawkitinarong, K., Payungporn, S., & Rotcheewaphan, S. (2024). Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03462-23

Vancouver

Prommi A, Wongjarit K, Petsong S, Somsukpiroh U, Faksri K, Kawkitinarong K, et al. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand. Microbiology Spectrum. 2024. doi:10.1128/spectrum.03462-23

BibTeX
@article{Prommi2024,
  author = {Prommi, Ajala and Wongjarit, Kanphai and Petsong, Suthidee and Somsukpiroh, Ubonwan and Faksri, Kiatichai and Kawkitinarong, Kamon and Payungporn, Sunchai and Rotcheewaphan, Suwatchareeporn},
  title = {Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.03462-23}
}
Kostenlos starten →